Skip to main content

2017 | OriginalPaper | Buchkapitel

6. Markov Decision Processes for Screening and Treatment of Chronic Diseases

verfasst von : Lauren N. Steimle, Brian T. Denton

Erschienen in: Markov Decision Processes in Practice

Verlag: Springer International Publishing

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

In recent years, Markov decision processes (MDPs) and partially observable Markov decision processes (POMDPs) have found important applications to medical decision making in the context of prevention, screening, and treatment of diseases. In this chapter, we provide a review of state-of-the-art models and methods that have been applied to chronic diseases. We provide a tutorial about how to formulate and solve these important problems emphasizing some of the challenges specific to chronic diseases such as diabetes, heart disease, and cancer. Then, we illustrate important considerations for model formulation and solution methods through two examples. The first example is an MDP model for optimal control of drug treatment decisions for managing the risk of heart disease and stroke in patients with type 2 diabetes. The second example is a POMDP model for optimal design of biomarker-based screening policies in the context of prostate cancer. We end the chapter with a discussion of the challenges of using MDPs and POMDPs for medical contexts and describe some important future directions for research.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Literatur
1.
Zurück zum Zitat World Health Organization, The top 10 causes of death (2013), Available at: who. int/mediacentre/factsheets/fs310/en/. 2014. World Health Organization, The top 10 causes of death (2013), Available at: who. int/mediacentre/factsheets/fs310/en/. 2014.
2.
Zurück zum Zitat M.L. Brandeau, F. Sainfort, W.P. Pierskalla, Operations Research and Health Care (Kluwer Academic Publishers, Boston, 2004) M.L. Brandeau, F. Sainfort, W.P. Pierskalla, Operations Research and Health Care (Kluwer Academic Publishers, Boston, 2004)
3.
Zurück zum Zitat B.T. Denton, Handbook of Healthcare Operations Management: Methods and Applications (Springer, New York, 2013)CrossRef B.T. Denton, Handbook of Healthcare Operations Management: Methods and Applications (Springer, New York, 2013)CrossRef
4.
Zurück zum Zitat G.S. Zaric, Operations Research and Health Care Policy (Springer, New York, 2013)CrossRef G.S. Zaric, Operations Research and Health Care Policy (Springer, New York, 2013)CrossRef
5.
Zurück zum Zitat O. Alagoz, L.M. Maillart, A.J. Schaefer, M.S. Roberts, The optimal timing of living donor liver transplantation. Manag. Sci. 50 (10), 1420–1430 (2004)CrossRef O. Alagoz, L.M. Maillart, A.J. Schaefer, M.S. Roberts, The optimal timing of living donor liver transplantation. Manag. Sci. 50 (10), 1420–1430 (2004)CrossRef
6.
Zurück zum Zitat O. Alagoz, C.L. Bryce, S.M. Shechter, A.J. Schaefer, C.-C.H. Chang, D.C. Angus, M.S. Roberts, Incorporating biological natural history in simulation models: empiric estimates of the progression of end-stage liver disease. Med. Decis. Mak. 25, 620–632 (2005)CrossRef O. Alagoz, C.L. Bryce, S.M. Shechter, A.J. Schaefer, C.-C.H. Chang, D.C. Angus, M.S. Roberts, Incorporating biological natural history in simulation models: empiric estimates of the progression of end-stage liver disease. Med. Decis. Mak. 25, 620–632 (2005)CrossRef
7.
Zurück zum Zitat O. Alagoz, L.M. Maillart, A.J. Schaefer, M.S. Roberts, Which waiting lists should an end-stage liver disease patient join? Technical Report, University of Pittsburgh, 2006 O. Alagoz, L.M. Maillart, A.J. Schaefer, M.S. Roberts, Which waiting lists should an end-stage liver disease patient join? Technical Report, University of Pittsburgh, 2006
8.
Zurück zum Zitat O. Alagoz, L.M. Maillart, A.J. Schaefer, M.S. Roberts, Choosing among living-donor and cadaveric livers. Manag. Sci. 53 (11), 1702–1715 (2007)CrossRef O. Alagoz, L.M. Maillart, A.J. Schaefer, M.S. Roberts, Choosing among living-donor and cadaveric livers. Manag. Sci. 53 (11), 1702–1715 (2007)CrossRef
9.
Zurück zum Zitat D.L. Segev, S.E. Gentry, D.S. Warren, B. Reeb, R.A. Montgomery, Kidney paired donation and optimizing the use of liver donor organs. J. Am. Med. Assoc. 295, 1655–1663 (2005) D.L. Segev, S.E. Gentry, D.S. Warren, B. Reeb, R.A. Montgomery, Kidney paired donation and optimizing the use of liver donor organs. J. Am. Med. Assoc. 295, 1655–1663 (2005)
10.
Zurück zum Zitat S.A. Zenios, G.M. Chertow, L.M. Wein, Dynamic allocation of kidneys to candidates on the trasplant waiting list. Oper. Res. 48 (4), 549–569 (2000)CrossRef S.A. Zenios, G.M. Chertow, L.M. Wein, Dynamic allocation of kidneys to candidates on the trasplant waiting list. Oper. Res. 48 (4), 549–569 (2000)CrossRef
11.
Zurück zum Zitat X. Su, S. Zenios, Patient choice in kidney allocation: the role of the queuing discipline. Manuf. Serv. Oper. Manag. 6 (4), 280–301 (2005) X. Su, S. Zenios, Patient choice in kidney allocation: the role of the queuing discipline. Manuf. Serv. Oper. Manag. 6 (4), 280–301 (2005)
12.
Zurück zum Zitat L.M. Maillart, J.S. Ivy, D. Kathleen, S. Ransom, Assessing dynamic breast cancer screening policies. Oper. Res. 56 (6), 1411–1427 (2008)CrossRef L.M. Maillart, J.S. Ivy, D. Kathleen, S. Ransom, Assessing dynamic breast cancer screening policies. Oper. Res. 56 (6), 1411–1427 (2008)CrossRef
13.
Zurück zum Zitat J. Chhatwal, O. Alagoz, E.S. Burnside, Optimal breast biopsy decision-making based on mammographic features and demographic factors. Oper. Res. 58 (6), 1577–1591 (2010)CrossRef J. Chhatwal, O. Alagoz, E.S. Burnside, Optimal breast biopsy decision-making based on mammographic features and demographic factors. Oper. Res. 58 (6), 1577–1591 (2010)CrossRef
14.
Zurück zum Zitat E.K. Lee, T. Fox, I. Crocker, Integer programming applied to intensity-modulated radiation therapy treatment planning. Ann. Oper. Res. 119, 165–181 (2003)CrossRef E.K. Lee, T. Fox, I. Crocker, Integer programming applied to intensity-modulated radiation therapy treatment planning. Ann. Oper. Res. 119, 165–181 (2003)CrossRef
15.
Zurück zum Zitat A. Holder, Designing radiotherapy plans with elastic constraints and interior point methods. Health Care Manag. Sci. 6, 5–16 (2003)CrossRef A. Holder, Designing radiotherapy plans with elastic constraints and interior point methods. Health Care Manag. Sci. 6, 5–16 (2003)CrossRef
16.
Zurück zum Zitat F. Preciado-Walters, R. Rardin, M. Langer, V. Thai, A coupled column generation, mixed integer approach to optimal planning of intensity modulated radiation therapy for cancer. Math. Program. 101, 319–338 (2004)CrossRef F. Preciado-Walters, R. Rardin, M. Langer, V. Thai, A coupled column generation, mixed integer approach to optimal planning of intensity modulated radiation therapy for cancer. Math. Program. 101, 319–338 (2004)CrossRef
17.
Zurück zum Zitat E.K. Lee, R.J. Gallagher, D. Silvern, C. Wu, M. Zaider, Treatment planning for brachytherapy: an integer programming model, two computational approaches, and experiments with permanent prostate implant planning. Phys. Med. Biol. 44, 145–165 (1999)CrossRef E.K. Lee, R.J. Gallagher, D. Silvern, C. Wu, M. Zaider, Treatment planning for brachytherapy: an integer programming model, two computational approaches, and experiments with permanent prostate implant planning. Phys. Med. Biol. 44, 145–165 (1999)CrossRef
18.
Zurück zum Zitat S.M. Shechter, M.D. Bailey, A.J. Schaefer, M.S. Roberts, The optimal time to initiate HIV therapy under ordered health states. Oper. Res. 56 (1), 20–33 (2008)CrossRef S.M. Shechter, M.D. Bailey, A.J. Schaefer, M.S. Roberts, The optimal time to initiate HIV therapy under ordered health states. Oper. Res. 56 (1), 20–33 (2008)CrossRef
19.
Zurück zum Zitat E.H. Kaplan, Probability models of needle exchange. Oper. Res. 43 (4), 558–569 (1995)CrossRef E.H. Kaplan, Probability models of needle exchange. Oper. Res. 43 (4), 558–569 (1995)CrossRef
20.
Zurück zum Zitat G. Zaric, M.L. Brandeau, Optimal investment in a portfolio of HIV prevention programs. Med. Decis. Mak. 21, 391–408 (2001)CrossRef G. Zaric, M.L. Brandeau, Optimal investment in a portfolio of HIV prevention programs. Med. Decis. Mak. 21, 391–408 (2001)CrossRef
21.
Zurück zum Zitat R. Siegel, J. Ma, Z. Zou, A. Jemal, Cancer statistics, 2014. CA Cancer J. Clin. 64 (1), 9–29 (2014)CrossRef R. Siegel, J. Ma, Z. Zou, A. Jemal, Cancer statistics, 2014. CA Cancer J. Clin. 64 (1), 9–29 (2014)CrossRef
22.
Zurück zum Zitat T. Ayer, O. Alagoz, N.K. Stout, A POMDP approach to personalize mammography screening decisions. Oper. Res. 60 (5), 1019–1034 (2012)CrossRef T. Ayer, O. Alagoz, N.K. Stout, A POMDP approach to personalize mammography screening decisions. Oper. Res. 60 (5), 1019–1034 (2012)CrossRef
23.
Zurück zum Zitat O. Alagoz, H. Hsu, A.J. Schaefer, M.S. Roberts, Markov decision processes: a tool for sequential decision making under uncertainty. Med. Decis. Mak. 30 (4), 474–483 (2010)CrossRef O. Alagoz, H. Hsu, A.J. Schaefer, M.S. Roberts, Markov decision processes: a tool for sequential decision making under uncertainty. Med. Decis. Mak. 30 (4), 474–483 (2010)CrossRef
24.
Zurück zum Zitat A.J. Schaefer, M.D. Bailey, S.M. Shechter, M.S. Roberts, Modeling medical treatment using Markov decision processes, in Handbook of Operations Research/Management Science Applications in Health Care, ed. by M. Brandeau, F. Sainfort, W. Pierskalla (Kluwer Academic, Dordrecht, 2004), pp. 597–616 A.J. Schaefer, M.D. Bailey, S.M. Shechter, M.S. Roberts, Modeling medical treatment using Markov decision processes, in Handbook of Operations Research/Management Science Applications in Health Care, ed. by M. Brandeau, F. Sainfort, W. Pierskalla (Kluwer Academic, Dordrecht, 2004), pp. 597–616
25.
Zurück zum Zitat E. Regnier, S.M. Shechter, State-space size considerations for disease-progression models. Stat. Med. 32 (22), 3862–3880 (2013)CrossRef E. Regnier, S.M. Shechter, State-space size considerations for disease-progression models. Stat. Med. 32 (22), 3862–3880 (2013)CrossRef
26.
Zurück zum Zitat G.E. Monohan, A survey of partially observable Markov decision processes: theory, models, and algorithms. Manag. Sci. 28 (1), 1–16 (1982)CrossRef G.E. Monohan, A survey of partially observable Markov decision processes: theory, models, and algorithms. Manag. Sci. 28 (1), 1–16 (1982)CrossRef
27.
Zurück zum Zitat W.S. Lovejoy, A survey of algorithmic methods for partially observed Markov decision processes. Ann. Oper. Res. 28, 47–66 (1991)CrossRef W.S. Lovejoy, A survey of algorithmic methods for partially observed Markov decision processes. Ann. Oper. Res. 28, 47–66 (1991)CrossRef
28.
Zurück zum Zitat K.A. Anderson, P.M. Odel, P.W.F. Wilson, W.B. Kannel, Cardiovascular disease risk profiles. Am. Heart J. 121, 293–298 (1991)CrossRef K.A. Anderson, P.M. Odel, P.W.F. Wilson, W.B. Kannel, Cardiovascular disease risk profiles. Am. Heart J. 121, 293–298 (1991)CrossRef
29.
Zurück zum Zitat P.A. Wolf, R.B. D’Agostino, A.J. Belanger, W.B. Kannel, Probability of stroke: a risk profile from the Framingham study. Stroke 22 (3), 312–318 (1991)CrossRef P.A. Wolf, R.B. D’Agostino, A.J. Belanger, W.B. Kannel, Probability of stroke: a risk profile from the Framingham study. Stroke 22 (3), 312–318 (1991)CrossRef
30.
Zurück zum Zitat P.W.F Wilson, R.B. D?Agostino, D. Levy, A.M. Belanger, H. Silbershatz, W.B. Kannel, Prediction of coronary heart disease using risk factor categories. Circulation 97 (18), 1837–1847 (1998) P.W.F Wilson, R.B. D?Agostino, D. Levy, A.M. Belanger, H. Silbershatz, W.B. Kannel, Prediction of coronary heart disease using risk factor categories. Circulation 97 (18), 1837–1847 (1998)
31.
Zurück zum Zitat R.C. Turner, The uk prospective diabetes study - a review. Diabetes Care 21, C35–C38 (1998)CrossRef R.C. Turner, The uk prospective diabetes study - a review. Diabetes Care 21, C35–C38 (1998)CrossRef
32.
Zurück zum Zitat T.M.E. Davis, H. Millns, I.M. Stratton, R.R. Holman, R.C. Turner, Risk factors for stroke in type 2 diabetes mellitus - United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch. Intern. Med. 159 (10), 1097–1103 (1999)CrossRef T.M.E. Davis, H. Millns, I.M. Stratton, R.R. Holman, R.C. Turner, Risk factors for stroke in type 2 diabetes mellitus - United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch. Intern. Med. 159 (10), 1097–1103 (1999)CrossRef
33.
Zurück zum Zitat R.J. Stevens, V. Kothari, A.I. Adler, I.M. Stratton, R.R. Holman, The UKPDS risk engine: a model for the risk of coronary heart disease in type ii diabetes (UKPDS 56). Clin. Sci. 101 (6), 671–679 (2001)CrossRef R.J. Stevens, V. Kothari, A.I. Adler, I.M. Stratton, R.R. Holman, The UKPDS risk engine: a model for the risk of coronary heart disease in type ii diabetes (UKPDS 56). Clin. Sci. 101 (6), 671–679 (2001)CrossRef
34.
Zurück zum Zitat V. Kothari, R.J. Stevens, A.I. Adler, I.M. Stratton, S.E. Manley, H.A. Neil, R.R. Holman et al., UKPDS 60 risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33 (7), 1776–1781 (2002)CrossRef V. Kothari, R.J. Stevens, A.I. Adler, I.M. Stratton, S.E. Manley, H.A. Neil, R.R. Holman et al., UKPDS 60 risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33 (7), 1776–1781 (2002)CrossRef
35.
Zurück zum Zitat D.C. Goff, D.M. Lloyd-Jones, G. Bennett, C.J. O’Donnell, S. Coady, J. Robinson, 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J. Am. Coll. Cardiol. 129, S49–S73 (2014) D.C. Goff, D.M. Lloyd-Jones, G. Bennett, C.J. O’Donnell, S. Coady, J. Robinson, 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J. Am. Coll. Cardiol. 129, S49–S73 (2014)
36.
Zurück zum Zitat S.L. Murphy, J. Xu, K.D. Kochanek, Deaths: final data for 2010. National Vital Statistics Reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics. Natl. Vital Stat. Rep. 61 (4), 1–117 (2013) S.L. Murphy, J. Xu, K.D. Kochanek, Deaths: final data for 2010. National Vital Statistics Reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics. Natl. Vital Stat. Rep. 61 (4), 1–117 (2013)
37.
Zurück zum Zitat D. Gold, M.R. Stevenson, D.G. Fryback, HALYS and QALYS and DALYS, oh my: similarities and differences in summary measures of population health. Annu. Rev. Public Health 23, 115–134 (2002)CrossRef D. Gold, M.R. Stevenson, D.G. Fryback, HALYS and QALYS and DALYS, oh my: similarities and differences in summary measures of population health. Annu. Rev. Public Health 23, 115–134 (2002)CrossRef
38.
Zurück zum Zitat K.L. Rascati, The $64,000 question – what is a quality-adjusted life year worth? Clin. Ther. 28 (7), 1042–1043 (2006)CrossRef K.L. Rascati, The $64,000 question – what is a quality-adjusted life year worth? Clin. Ther. 28 (7), 1042–1043 (2006)CrossRef
39.
Zurück zum Zitat D.P. Bertsekas, J.N. Tsitsiklis, Neuro-dynamic programming: an overview, in Proceedings of the 34th IEEE Conference on Decision and Control, 1995, vol. 1 (IEEE, New York, 1995), pp. 560–564 D.P. Bertsekas, J.N. Tsitsiklis, Neuro-dynamic programming: an overview, in Proceedings of the 34th IEEE Conference on Decision and Control, 1995, vol. 1 (IEEE, New York, 1995), pp. 560–564
40.
41.
Zurück zum Zitat M.L. Puterman, Markov Decision Processes: Discrete Stochastic Dynamic Programming. (Wiley, Hoboken, 1994) M.L. Puterman, Markov Decision Processes: Discrete Stochastic Dynamic Programming. (Wiley, Hoboken, 1994)
42.
Zurück zum Zitat M. Kurt, B.T. Denton, A.J. Schaefer, N.D. Shah, S.A. Smith, The structure of optimal statin initiation policies for patients with type 2 diabetes. IIE Trans. Healthc. Eng. 1, 49–65 (2011)CrossRef M. Kurt, B.T. Denton, A.J. Schaefer, N.D. Shah, S.A. Smith, The structure of optimal statin initiation policies for patients with type 2 diabetes. IIE Trans. Healthc. Eng. 1, 49–65 (2011)CrossRef
43.
Zurück zum Zitat R.D. Smallwood, E.J. Sondik, The optimal control of partially observable Markov processes over a finite horizon. Oper. Res. 21 (5), 1071–1088 (1973)CrossRef R.D. Smallwood, E.J. Sondik, The optimal control of partially observable Markov processes over a finite horizon. Oper. Res. 21 (5), 1071–1088 (1973)CrossRef
44.
Zurück zum Zitat A. Cassandra, M.L. Littman, N.L. Zhang, Incremental pruning: a simple, fast, exact method for partially observable Markov decision processes, in Proceedings Thirteenth Annual Conference on Uncertainty in Artificial Intelligence, San Francisco, CA (1997), pp. 54–61 A. Cassandra, M.L. Littman, N.L. Zhang, Incremental pruning: a simple, fast, exact method for partially observable Markov decision processes, in Proceedings Thirteenth Annual Conference on Uncertainty in Artificial Intelligence, San Francisco, CA (1997), pp. 54–61
46.
Zurück zum Zitat J.E. Eckles, Optimum replacement of stochastically failing systems, Ph.D. Dissertation, Dept. Eng.-Econ. Syst., Stanford University, Stanford (1966) J.E. Eckles, Optimum replacement of stochastically failing systems, Ph.D. Dissertation, Dept. Eng.-Econ. Syst., Stanford University, Stanford (1966)
47.
Zurück zum Zitat W.S. Lovejoy, Computationally feasible bounds for partially observed Markov decision processes. Oper. Res. 39 (1), 162–175 (1991)CrossRef W.S. Lovejoy, Computationally feasible bounds for partially observed Markov decision processes. Oper. Res. 39 (1), 162–175 (1991)CrossRef
48.
Zurück zum Zitat Centers for Disease Control and Prevention, National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. US Department of Health and Human Services, Atlanta, GA, 2014 Centers for Disease Control and Prevention, National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. US Department of Health and Human Services, Atlanta, GA, 2014
49.
Zurück zum Zitat V. Snow, M.D. Aronson, E.R. Hornbake, C. Mottur-Pilson, K.B. Weiss, Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 140 (8), 644–649 (2004)CrossRef V. Snow, M.D. Aronson, E.R. Hornbake, C. Mottur-Pilson, K.B. Weiss, Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 140 (8), 644–649 (2004)CrossRef
50.
Zurück zum Zitat D.G. Manuel, K. Kwong, P. Tanuseputro, J. Lim, C.A. Mustard, G.M. Anderson, S. Ardal, D.A. Alter, A. Laupacis, Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. Br. Med. J. 332 (7555), 1419–1422 (2006)CrossRef D.G. Manuel, K. Kwong, P. Tanuseputro, J. Lim, C.A. Mustard, G.M. Anderson, S. Ardal, D.A. Alter, A. Laupacis, Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. Br. Med. J. 332 (7555), 1419–1422 (2006)CrossRef
51.
Zurück zum Zitat P.N. Durrington, H. Prais, D. Bhatnagar, M. France, V. Crowley, J. Khan, J. Morgan, Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet, 353 (9149), 278–281 (1999)CrossRef P.N. Durrington, H. Prais, D. Bhatnagar, M. France, V. Crowley, J. Khan, J. Morgan, Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet, 353 (9149), 278–281 (1999)CrossRef
52.
Zurück zum Zitat B.T. Denton, M. Kurt, N.D. Shah, S.C. Bryant, S.A. Smith, Optimizing the start time of statin therapy for patients with diabetes. Med. Decis. Mak. 29 (3), 351–367 (2009)CrossRef B.T. Denton, M. Kurt, N.D. Shah, S.C. Bryant, S.A. Smith, Optimizing the start time of statin therapy for patients with diabetes. Med. Decis. Mak. 29 (3), 351–367 (2009)CrossRef
53.
Zurück zum Zitat J.E. Mason, D.A. England, B.T. Denton, S.A. Smith, M. Kurt, N.D. Shah, Optimizing statin treatment decisions for diabetes patients in the presence of uncertain future adherence. Med. Decis. Mak. 32 (1), 154–166 (2012)CrossRef J.E. Mason, D.A. England, B.T. Denton, S.A. Smith, M. Kurt, N.D. Shah, Optimizing statin treatment decisions for diabetes patients in the presence of uncertain future adherence. Med. Decis. Mak. 32 (1), 154–166 (2012)CrossRef
54.
Zurück zum Zitat J.E. Mason, B.T. Denton, N.D. Shah, S.A. Smith, Optimizing the simultaneous management of blood pressure and cholesterol for type 2 diabetes patients. Eur. J. Oper. Res. 233 (3), 727–738 (2014)CrossRef J.E. Mason, B.T. Denton, N.D. Shah, S.A. Smith, Optimizing the simultaneous management of blood pressure and cholesterol for type 2 diabetes patients. Eur. J. Oper. Res. 233 (3), 727–738 (2014)CrossRef
55.
Zurück zum Zitat D.K. Miller, S.M. Homan, Determining transition probabilities confusion and suggestions. Med. Decis. Mak. 14 (1), 52–58 (1994)CrossRef D.K. Miller, S.M. Homan, Determining transition probabilities confusion and suggestions. Med. Decis. Mak. 14 (1), 52–58 (1994)CrossRef
56.
Zurück zum Zitat M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein, Cost-Effectiveness in Health and Medicine (Oxford University Press, New York, 1996) M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein, Cost-Effectiveness in Health and Medicine (Oxford University Press, New York, 1996)
57.
Zurück zum Zitat P.A. James, S. Oparil, B.L. Carter, W.C. Cushman, C. Dennison-Himmelfarb, J. Handler, D.T. Lackland, M.L. LeFevre, T.D. MacKenzie, O. Ogedegbe et al., 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (jnc 8). JAMA, 311 (5), 507–520 (2014)CrossRef P.A. James, S. Oparil, B.L. Carter, W.C. Cushman, C. Dennison-Himmelfarb, J. Handler, D.T. Lackland, M.L. LeFevre, T.D. MacKenzie, O. Ogedegbe et al., 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (jnc 8). JAMA, 311 (5), 507–520 (2014)CrossRef
58.
Zurück zum Zitat N.J. Stone, J.G. Robinson, A.H. Lichtenstein, 2013 acc/aha guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the american college of cardiology/american heart association task force on practice guidelines. J. Am. Coll. Cardiol. 163, 2889–2934 (2014); correction. J. Am. Coll. Cardiol. 63 (25), 3024–3025 (2014) N.J. Stone, J.G. Robinson, A.H. Lichtenstein, 2013 acc/aha guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the american college of cardiology/american heart association task force on practice guidelines. J. Am. Coll. Cardiol. 163, 2889–2934 (2014); correction. J. Am. Coll. Cardiol. 63 (25), 3024–3025 (2014)
59.
Zurück zum Zitat O.H. Franco, E.W. Steyerberg, F.B. Hu, J. Mackenbach, W. Nusselder, Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch. Intern. Med. 167 (11), 1145–1151 (2007)CrossRef O.H. Franco, E.W. Steyerberg, F.B. Hu, J. Mackenbach, W. Nusselder, Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch. Intern. Med. 167 (11), 1145–1151 (2007)CrossRef
60.
Zurück zum Zitat A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr., D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr. et al., The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289 (19), 2560–2571 (2003)CrossRef A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr., D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr. et al., The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289 (19), 2560–2571 (2003)CrossRef
61.
Zurück zum Zitat National Cholesterol Education Program NCEP Expert Panel, Third report of the National Cholesterol Education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 (25), 3143 (2002) National Cholesterol Education Program NCEP Expert Panel, Third report of the National Cholesterol Education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 (25), 3143 (2002)
62.
Zurück zum Zitat J. Shah, N.D. Mason, M. Kurt, B.T. Denton, A. Schaefer, V. Montori, S. Smith, Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients. Plos One 6 (1), e16170 (2011) J. Shah, N.D. Mason, M. Kurt, B.T. Denton, A. Schaefer, V. Montori, S. Smith, Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients. Plos One 6 (1), e16170 (2011)
63.
Zurück zum Zitat J. Zhang, H. Balasubramanian, B.T. Denton, N. Shah, B. Inman, Optimization of prostate cancer screening decisions: a comparison of patient and societal perspectives. Med. Decis. Mak. 32 (2), 337–349 (2011). doi:10.1177/0272989X11416513CrossRef J. Zhang, H. Balasubramanian, B.T. Denton, N. Shah, B. Inman, Optimization of prostate cancer screening decisions: a comparison of patient and societal perspectives. Med. Decis. Mak. 32 (2), 337–349 (2011). doi:10.1177/0272989X11416513CrossRef
64.
Zurück zum Zitat J. Zhang, B.T. Denton, H. Balasubramanian, N.D. Shah, B.A. Inman, Optimization of prostate biopsy referral decisions. Manuf. Serv. Oper. Manag. 14 (4), 529–547 (2012) J. Zhang, B.T. Denton, H. Balasubramanian, N.D. Shah, B.A. Inman, Optimization of prostate biopsy referral decisions. Manuf. Serv. Oper. Manag. 14 (4), 529–547 (2012)
65.
Zurück zum Zitat G.P. Haas, R.F. Delongchamps, V. Jones, V. Chandan, A.M. Seriod, A.J. Vickers, M. Jumbelic, G. Threatte, R. Korets, H. Lilja, G. De la Roza, Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J. Natl. Cancer Inst. 99, 1484–1849 (2007)CrossRef G.P. Haas, R.F. Delongchamps, V. Jones, V. Chandan, A.M. Seriod, A.J. Vickers, M. Jumbelic, G. Threatte, R. Korets, H. Lilja, G. De la Roza, Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J. Natl. Cancer Inst. 99, 1484–1849 (2007)CrossRef
66.
Zurück zum Zitat I.M. Thompson, D.P. Ankerst, C. Chi, P.J. Goodman, C.M. Tangen, M.S. Lucia, Z. Feng, H.L. Parnes, C.A. Coltman, Assessing prostate cancer risk: results from the prostate cancer prevention trial. J. Natl. Cancer Inst. 98 (8), 529–534 (2006)CrossRef I.M. Thompson, D.P. Ankerst, C. Chi, P.J. Goodman, C.M. Tangen, M.S. Lucia, Z. Feng, H.L. Parnes, C.A. Coltman, Assessing prostate cancer risk: results from the prostate cancer prevention trial. J. Natl. Cancer Inst. 98 (8), 529–534 (2006)CrossRef
67.
Zurück zum Zitat R. Gulati, L. Inoue, J. Katcher, W. Hazelton, R. Etzioni, Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics 11 (4), 707–719 (2010)CrossRef R. Gulati, L. Inoue, J. Katcher, W. Hazelton, R. Etzioni, Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics 11 (4), 707–719 (2010)CrossRef
68.
Zurück zum Zitat W.J. Catalona, P.T. Scardino, J.R. Beck, B.J. Miles, G.W. Chodak, R.A. Thisted, Conservative management of prostate cancer. N. Engl. J. Med. 330 (25), 1830–1832 (1994) W.J. Catalona, P.T. Scardino, J.R. Beck, B.J. Miles, G.W. Chodak, R.A. Thisted, Conservative management of prostate cancer. N. Engl. J. Med. 330 (25), 1830–1832 (1994)
69.
Zurück zum Zitat L. Bubendorf, A. Schöpfer, U. Wagner, G. Sauter, H. Moch, N. Willi, T.C. Gasser, M.J. Mihatsch, Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31 (5), 578–583 (2000)CrossRef L. Bubendorf, A. Schöpfer, U. Wagner, G. Sauter, H. Moch, N. Willi, T.C. Gasser, M.J. Mihatsch, Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31 (5), 578–583 (2000)CrossRef
70.
Zurück zum Zitat M. Heron, Deaths: leading causes for 2004. Natl. Vital Stat. Rep. 56 (5), 1–96 (2007) M. Heron, Deaths: leading causes for 2004. Natl. Vital Stat. Rep. 56 (5), 1–96 (2007)
72.
Zurück zum Zitat G.S. Kulkarni, S.M.H. Alibhai, A. Finelli, N.E. Fleshner, M.A.S. Jewett, S.R. Lopushinsky, A.M. Bayoumi, Cost-effectiveness analysis of immediate radical cystectomy versus intravesical bacillus Calmette-Guerin therapy for high-risk, high-grade (t1g3) bladder cancer. Cancer 115 (23), 5450–5459 (2009)CrossRef G.S. Kulkarni, S.M.H. Alibhai, A. Finelli, N.E. Fleshner, M.A.S. Jewett, S.R. Lopushinsky, A.M. Bayoumi, Cost-effectiveness analysis of immediate radical cystectomy versus intravesical bacillus Calmette-Guerin therapy for high-risk, high-grade (t1g3) bladder cancer. Cancer 115 (23), 5450–5459 (2009)CrossRef
73.
Zurück zum Zitat K.E. Bremner, C.A.K.Y. Chong, G. Tomlinson, S.M.H Alibhai, M.D Krahn, A review and meta-analysis of prostate cancer utilities. Med. Decis. Making 27, 288–298 (2007) K.E. Bremner, C.A.K.Y. Chong, G. Tomlinson, S.M.H Alibhai, M.D Krahn, A review and meta-analysis of prostate cancer utilities. Med. Decis. Making 27, 288–298 (2007)
74.
Zurück zum Zitat G.E. Monohan, A survey of partially observable Markov decision processes: theory, mondels, and algorithms. Manag. Sci. 28 (1), 1–16 (1982)CrossRef G.E. Monohan, A survey of partially observable Markov decision processes: theory, mondels, and algorithms. Manag. Sci. 28 (1), 1–16 (1982)CrossRef
75.
Zurück zum Zitat L.P. Kaelbling, M.L. Littman, A.R. Cassandra, Planning and acting in partially observable stochastic domains. Artif. Intell. 101 (1), 99–134 (1998)CrossRef L.P. Kaelbling, M.L. Littman, A.R. Cassandra, Planning and acting in partially observable stochastic domains. Artif. Intell. 101 (1), 99–134 (1998)CrossRef
76.
Zurück zum Zitat D. Underwood, Risk-based simulation optimization of PSA-based prostate cancer screening. Ph.D. Thesis, North Carolina State University, 2015 D. Underwood, Risk-based simulation optimization of PSA-based prostate cancer screening. Ph.D. Thesis, North Carolina State University, 2015
77.
Zurück zum Zitat G.N. Iyengar, Robust dynamic programming. Math. Oper. Res. 30 (2), 257–280 (2005)CrossRef G.N. Iyengar, Robust dynamic programming. Math. Oper. Res. 30 (2), 257–280 (2005)CrossRef
78.
Zurück zum Zitat A. Nilim, L.E. Ghaoui, Robust control of Markov decision processes with uncertain transition matrices. Oper. Res. 55 (5), 780–798 (2005)CrossRef A. Nilim, L.E. Ghaoui, Robust control of Markov decision processes with uncertain transition matrices. Oper. Res. 55 (5), 780–798 (2005)CrossRef
Metadaten
Titel
Markov Decision Processes for Screening and Treatment of Chronic Diseases
verfasst von
Lauren N. Steimle
Brian T. Denton
Copyright-Jahr
2017
DOI
https://doi.org/10.1007/978-3-319-47766-4_6